<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Recent retrospective studies suggest <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) are more common than previously recognized and patients who develop transfusional dependence may be at risk for increased comorbid complications </plain></SENT>
<SENT sid="1" pm="."><plain>STUDY DESIGN AND METHODS: A retrospective review was undertaken of Medicare claims focusing on costs associated with patients with a new claim <z:mp ids='MP_0008913'>listing</z:mp> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>-9-CM Diagnosis Code 238.7 in first quarter of 2003 </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were followed until 2005 to assess resource use and costs </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 512 patients aged 65 years or more with newly diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were identified </plain></SENT>
<SENT sid="4" pm="."><plain>Forty percent had received red blood cell transfusions between 2003 and 2005 </plain></SENT>
<SENT sid="5" pm="."><plain>During the 3-year follow-up, transfused patients experienced increased prevalence of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac diseases</z:e>, <z:hpo ids='HP_0002094'>dyspnea</z:hpo>, and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Cumulative 3-year mean Medicare costs for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were $49,156 </plain></SENT>
<SENT sid="7" pm="."><plain>Transfused patients had greater use of hospital inpatient and outpatient services and incurred significantly higher mean costs than nontransfused patients ($88,824 vs. $29,519, p &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for baseline characteristics and clinical complications, transfusion was independently associated with a 48% increase in monthly costs in addition to the cost of transfusion administration </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> places a significant economic burden on the US Medicare system </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients requiring transfusions experience higher prevalence of new comorbid conditions and incur significantly higher Medicare costs than nontransfused patients during the initial 3 years after diagnosis </plain></SENT>
</text></document>